US Stock Insider Trading | Century Therapeutics disclosed 1 insider transaction on March 10

K-LinePoet · 2026-03-11T02:11:45+00:00

On March 10, 2026, Century Therapeutics disclosed that Director Brent sold 463 shares on March 6, for a total transaction amount of $1,185.28. Recently, there have been other buy and sell transactions by executives. The company focuses on developing allogeneic cell therapies to address medical needs.

K-LinePoet

2026-03-11 02:11:45

Abstract generation in progress

On March 10, 2026, Century Therapeutics (IPSC) disclosed an insider trading activity. Director Pfeiffenberger Brent sold 463 shares on March 6, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Director	Pfeiffenberger Brent	March 6, 2026	Sell	463	2.56	1,185.28
February 18, 2026	Director	Pfeiffenberger Brent	February 13, 2026	Sell	31,200	1.75	54,600
February 5, 2026	Executive	Carr Douglas	February 3, 2026	Sell	323	1.82	588.51
January 6, 2026	Executive	Cowan Chad	January 2, 2026	Sell	1,611	1.00	1,602.95
December 29, 2025	Executive	Cowan Chad	December 22, 2025	Buy	58,100	0.85	48,350
December 16, 2025	Director	Pfeiffenberger Brent	December 12, 2025	Buy	52,000	0.58	30,400
December 12, 2025	Director	Pfeiffenberger Brent	December 10, 2025	Sell	463	0.53	243.54
December 10, 2025	Executive	Russotti Gregory	December 8, 2025	Sell	526	0.53	279.83
December 10, 2025	Executive	Carr Douglas	December 8, 2025	Sell	257	0.53	136.72
November 24, 2025	Executive	Cowan Chad	November 20, 2025	Sell	5,462	0.50	2,736.46

[Company Information]

Century Therapeutics, Inc. was incorporated on March 5, 2018, in Delaware. The company is an innovative biotechnology firm dedicated to developing transformative allogeneic cell therapies to create products for treating solid tumors and hematologic malignancies with significant unmet medical needs. The company has established a comprehensive allogeneic cell therapy platform, including industry-leading induced pluripotent stem cells (iPSC), differentiation technologies to generate immune effector cells from iPSC or iPSC-derived cells, clustered CRISPR-mediated precise gene editing that allows for the integration of multiple transgenes and removal of target genes to optimize cell product performance, advanced protein engineering capabilities to develop proprietary next-generation chimeric antigen receptor (CAR) cell products that are influenced by the host immune system, and state-of-the-art manufacturing capabilities designed to minimize product development and supply risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.